Open main menu
ICRPaedia β

Pages with the most revisions

Showing below up to 500 results in range #51 to #550.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. Types of materials‏‎ (5 revisions)
  2. Reference Animal and Plant‏‎ (4 revisions)
  3. Kp index‏‎ (4 revisions)
  4. Protective action‏‎ (4 revisions)
  5. Source-related assessment‏‎ (4 revisions)
  6. Forbiddenness‏‎ (4 revisions)
  7. Aerodynamic diameter‏‎ (4 revisions)
  8. ICRP‏‎ (4 revisions)
  9. Reference bioassay function‏‎ (4 revisions)
  10. Diagnostic reference level‏‎ (4 revisions)
  11. Risk‏‎ (4 revisions)
  12. Senescence‏‎ (4 revisions)
  13. Air-kerma, product‏‎ (4 revisions)
  14. Fractionation sensitivity‏‎ (4 revisions)
  15. Optimisation‏‎ (4 revisions)
  16. Sievert‏‎ (4 revisions)
  17. Air kerma at the patient entrance reference point‏‎ (4 revisions)
  18. S coefficient (radiation weighted)‏‎ (4 revisions)
  19. Non-maleficence‏‎ (4 revisions)
  20. High linear energy transfer radiation‏‎ (4 revisions)
  21. Direct bioassay‏‎ (4 revisions - redirect page)
  22. Bioassay‏‎ (4 revisions)
  23. Calculating Radon Doses‏‎ (4 revisions)
  24. Computed tomography dose index‏‎ (4 revisions)
  25. Mass median diameter‏‎ (4 revisions)
  26. Alpha decay‏‎ (4 revisions)
  27. Effective charge number‏‎ (4 revisions)
  28. Math‏‎ (4 revisions)
  29. Programmed cell death‏‎ (4 revisions)
  30. Effective half-life‏‎ (4 revisions)
  31. Averted dose‏‎ (4 revisions)
  32. DS02‏‎ (3 revisions)
  33. Fluoroscopically guided interventions‏‎ (3 revisions)
  34. Annual dose‏‎ (3 revisions)
  35. Potential exposure‏‎ (3 revisions)
  36. Rigidity threshold‏‎ (3 revisions)
  37. Dose of record (E)‏‎ (3 revisions)
  38. Low Earth orbit‏‎ (3 revisions)
  39. Accountability‏‎ (3 revisions)
  40. X ray‏‎ (3 revisions)
  41. Half-life, physical‏‎ (3 revisions)
  42. Cell death‏‎ (3 revisions)
  43. Contamination‏‎ (3 revisions)
  44. Exponential survival curve‏‎ (3 revisions)
  45. Unsealed source‏‎ (3 revisions)
  46. Xerostomia‏‎ (3 revisions)
  47. Annual limit on intake‏‎ (3 revisions)
  48. Dose per content function‏‎ (3 revisions)
  49. Interphase death‏‎ (3 revisions)
  50. Equity‏‎ (3 revisions)
  51. Test‏‎ (3 revisions)
  52. Graded approach‏‎ (3 revisions)
  53. Public exposure‏‎ (3 revisions)
  54. Fractionation‏‎ (3 revisions)
  55. Uptake‏‎ (3 revisions)
  56. Active (red) bone marrow‏‎ (3 revisions)
  57. Utilitarian ethics‏‎ (3 revisions)
  58. Granulocyte-macrophage colony-stimulating factor‏‎ (3 revisions)
  59. Operational quantity‏‎ (3 revisions)
  60. Value judgement‏‎ (3 revisions)
  61. Granulocyte colony-stimulating factor‏‎ (3 revisions)
  62. Coster-Kronig transition‏‎ (3 revisions)
  63. Emergency preparedness‏‎ (3 revisions)
  64. Valvular heart disease‏‎ (3 revisions)
  65. Gray‏‎ (3 revisions)
  66. Personal dose equivalent‏‎ (3 revisions)
  67. Principle of justification‏‎ (3 revisions)
  68. Radiofrequency ablation‏‎ (3 revisions)
  69. Iso-effect plots‏‎ (3 revisions)
  70. Emergency procedures‏‎ (3 revisions)
  71. Lifetime risk estimates‏‎ (3 revisions)
  72. Absolute risk‏‎ (3 revisions)
  73. Virtue ethics‏‎ (3 revisions)
  74. Auger transition‏‎ (3 revisions)
  75. Bystander effect‏‎ (3 revisions)
  76. Derived air concentration‏‎ (3 revisions)
  77. Dignity‏‎ (3 revisions)
  78. Isomers‏‎ (3 revisions)
  79. Employer‏‎ (3 revisions)
  80. Activity median thermodynamic diameter‏‎ (3 revisions)
  81. Voxel phantom‏‎ (3 revisions)
  82. Radiological Protection in Healthcare‏‎ (3 revisions - redirect page)
  83. Complex tissues‏‎ (3 revisions)
  84. Growth fraction‏‎ (3 revisions)
  85. Organ dose equivalent‏‎ (3 revisions)
  86. Excretion rate (instantaneous)‏‎ (3 revisions)
  87. Extrathoracic airways‏‎ (3 revisions)
  88. Galactic cosmic radiation‏‎ (3 revisions)
  89. Growth hormone (somatotropin)‏‎ (3 revisions)
  90. ICRP Publication 103‏‎ (3 revisions)
  91. DNA damage signalling‏‎ (3 revisions)
  92. Spread-out Bragg peak‏‎ (3 revisions)
  93. Fairness‏‎ (3 revisions)
  94. Absorption‏‎ (3 revisions)
  95. Gamma ray‏‎ (3 revisions)
  96. Recovery‏‎ (3 revisions)
  97. Dose equivalent‏‎ (3 revisions)
  98. Field-size effect (Volume effect)‏‎ (3 revisions)
  99. Gastrointestinal syndrome‏‎ (3 revisions)
  100. Wisdom‏‎ (3 revisions)
  101. Biomedical research volunteer‏‎ (3 revisions)
  102. Cardiomyopathy‏‎ (3 revisions)
  103. Dose limit‏‎ (3 revisions)
  104. Target region‏‎ (3 revisions)
  105. Flexible tissues‏‎ (3 revisions)
  106. Guide to the System of Radiological Protection‏‎ (3 revisions)
  107. Autonomy‏‎ (3 revisions)
  108. Dose‏‎ (3 revisions)
  109. Dose limits‏‎ (3 revisions)
  110. Fluence‏‎ (3 revisions)
  111. Constancy test‏‎ (3 revisions)
  112. Rigidity‏‎ (2 revisions)
  113. Dose-length product‏‎ (2 revisions)
  114. Security‏‎ (2 revisions)
  115. Incident‏‎ (2 revisions)
  116. Intermediate level waste‏‎ (2 revisions)
  117. Stenosis‏‎ (2 revisions)
  118. Equieffective dose‏‎ (2 revisions)
  119. Local DRL‏‎ (2 revisions)
  120. Expanded and aligned radiation field‏‎ (2 revisions)
  121. Tolerability‏‎ (2 revisions)
  122. Medical exposure‏‎ (2 revisions)
  123. Naturally occurring radioactive material‏‎ (2 revisions)
  124. Adventitious‏‎ (2 revisions)
  125. Working level month‏‎ (2 revisions)
  126. Habitual nose breather‏‎ (2 revisions)
  127. Hypertrophic cardiomyopathy‏‎ (2 revisions)
  128. Background dose (rate)‏‎ (2 revisions)
  129. Radiosensitivity, cellular‏‎ (2 revisions)
  130. Containment‏‎ (2 revisions)
  131. Detriment‏‎ (2 revisions)
  132. Dose-rate effect‏‎ (2 revisions)
  133. Inclusiveness‏‎ (2 revisions)
  134. Source-related‏‎ (2 revisions)
  135. Internal conversion electron‏‎ (2 revisions)
  136. Electron-capture decay‏‎ (2 revisions)
  137. LD 50/30‏‎ (2 revisions)
  138. Telangiectasia‏‎ (2 revisions)
  139. Member of the public‏‎ (2 revisions)
  140. Fluoroscopically or computed tomography guided interventions‏‎ (2 revisions)
  141. Unattached fraction‏‎ (2 revisions)
  142. Necrosis‏‎ (2 revisions)
  143. Patient entrance reference point‏‎ (2 revisions)
  144. Hypoplasia‏‎ (2 revisions)
  145. Backscatter detection system‏‎ (2 revisions)
  146. Potential recoverability correction factor‏‎ (2 revisions)
  147. Bradycardia‏‎ (2 revisions)
  148. Protective action guide‏‎ (2 revisions)
  149. Radiation worker‏‎ (2 revisions)
  150. Reference air kerma‏‎ (2 revisions)
  151. Decay constant‏‎ (2 revisions)
  152. Self-help protection‏‎ (2 revisions)
  153. Individual-related‏‎ (2 revisions)
  154. Dose of record Hp (10)‏‎ (2 revisions)
  155. Electrophysiology‏‎ (2 revisions)
  156. Storage‏‎ (2 revisions)
  157. Track structure‏‎ (2 revisions)
  158. Mendelian diseases‏‎ (2 revisions)
  159. Accreditation‏‎ (2 revisions)
  160. Neurological syndrome‏‎ (2 revisions)
  161. Genomic integrity‏‎ (2 revisions)
  162. Occupational exposure‏‎ (2 revisions)
  163. Hazard‏‎ (2 revisions)
  164. Peak skin dose‏‎ (2 revisions)
  165. Bragg peak‏‎ (2 revisions)
  166. Radioactive dispersion device‏‎ (2 revisions)
  167. Radon: Units of Measure‏‎ (2 revisions)
  168. Coronary heart disease‏‎ (2 revisions)
  169. Decommissioning‏‎ (2 revisions)
  170. ICRP Task Groups on Radiological Protection in Healthcare‏‎ (2 revisions)
  171. Dose-threshold‏‎ (2 revisions)
  172. Individual decontamination‏‎ (2 revisions)
  173. Subcutaneous tissue‏‎ (2 revisions)
  174. Low dose rate‏‎ (2 revisions)
  175. Transfer compartment‏‎ (2 revisions)
  176. Mitigation‏‎ (2 revisions)
  177. Fractional absorption in the gastrointestinal tract‏‎ (2 revisions)
  178. Action Level‏‎ (2 revisions)
  179. Upper reference levels‏‎ (2 revisions)
  180. Neurovascular syndrome‏‎ (2 revisions)
  181. Health Surveillance‏‎ (2 revisions)
  182. Pelagic‏‎ (2 revisions)
  183. Basal cell‏‎ (2 revisions)
  184. Practical radiological protection culture‏‎ (2 revisions)
  185. Branching fraction‏‎ (2 revisions)
  186. Chronic exposure‏‎ (2 revisions)
  187. Radioactive source‏‎ (2 revisions)
  188. Colony‏‎ (2 revisions)
  189. Cosmic Radiation in Aviation‏‎ (2 revisions)
  190. Reference biokinetic model‏‎ (2 revisions)
  191. Decontamination‏‎ (2 revisions)
  192. Relocation‏‎ (2 revisions)
  193. Diastasis‏‎ (2 revisions)
  194. Risk coefficient‏‎ (2 revisions)
  195. Individual monitoring‏‎ (2 revisions)
  196. Dose per unit intake coefficient‏‎ (2 revisions)
  197. Source term‏‎ (2 revisions)
  198. Emergency‏‎ (2 revisions)
  199. Latent time/period or latency interval‏‎ (2 revisions)
  200. Low level waste‏‎ (2 revisions)
  201. Exposure, external or internal‏‎ (2 revisions)
  202. Graft vs host disease‏‎ (2 revisions)
  203. Air-kerma, incident‏‎ (2 revisions)
  204. Heliosphere‏‎ (2 revisions)
  205. Qualified expert‏‎ (2 revisions)
  206. Class SR-0 gases‏‎ (2 revisions)
  207. Radioactive substance‏‎ (2 revisions)
  208. Reference individual‏‎ (2 revisions)
  209. Decontamination factor‏‎ (2 revisions)
  210. Remedial action‏‎ (2 revisions)
  211. ICRPædia Guide to Dose Coefficients‏‎ (2 revisions)
  212. Dose rate‏‎ (2 revisions)
  213. Intervention Level‏‎ (2 revisions)
  214. Emergency exposure situation‏‎ (2 revisions)
  215. Substantial radiation dose level‏‎ (2 revisions)
  216. Erythropoietin‏‎ (2 revisions)
  217. Exposure (in the context of inhalation)‏‎ (2 revisions)
  218. Transfer rate‏‎ (2 revisions)
  219. Multi-detector computed tomography‏‎ (2 revisions)
  220. Fractionation and dose delivery patterns‏‎ (2 revisions)
  221. Percutaneous coronary intervention‏‎ (2 revisions)
  222. Prevailing circumstances‏‎ (2 revisions)
  223. Broad beam therapy irradiation technique‏‎ (2 revisions)
  224. Class SR-1 gases‏‎ (2 revisions)
  225. Committed effective dose‏‎ (2 revisions)
  226. Radon Recommendations for Authorities‏‎ (2 revisions)
  227. Cost-benefit analysis‏‎ (2 revisions)
  228. Reference level‏‎ (2 revisions)
  229. Remediation‏‎ (2 revisions)
  230. Dichotomous‏‎ (2 revisions)
  231. Risk of Exposure to Radon‏‎ (2 revisions)
  232. Dose rate effectiveness factor‏‎ (2 revisions)
  233. South Atlantic anomaly‏‎ (2 revisions)
  234. Interventional procedure‏‎ (2 revisions)
  235. Emergency plan‏‎ (2 revisions)
  236. Ethics‏‎ (2 revisions)
  237. Lymphatic system‏‎ (2 revisions)
  238. ALARA‏‎ (2 revisions)
  239. Transforming growth factor‏‎ (2 revisions)
  240. Hierarchical tissues‏‎ (2 revisions)
  241. Area monitoring‏‎ (2 revisions)
  242. Pericarditis‏‎ (2 revisions)
  243. Benthic‏‎ (2 revisions)
  244. Principle of application of dose limits‏‎ (2 revisions)
  245. Bronchial region‏‎ (2 revisions)
  246. Class SR-2 gases‏‎ (2 revisions)
  247. Radioactivity‏‎ (2 revisions)
  248. Committed equivalent dose‏‎ (2 revisions)
  249. Radon Recommendations for Workplaces‏‎ (2 revisions)
  250. Deontological Ethics‏‎ (2 revisions)
  251. Repopulation‏‎ (2 revisions)
  252. Differentiation‏‎ (2 revisions)
  253. Routine monitoring‏‎ (2 revisions)
  254. ICRPædia Guide to Radon‏‎ (2 revisions)
  255. Special (non-routine) monitoring‏‎ (2 revisions)
  256. Lifetime risk‏‎ (2 revisions)
  257. Macrophage colony stimulating factor‏‎ (2 revisions)
  258. Multiplicative risk projection model‏‎ (2 revisions)
  259. Activity‏‎ (2 revisions)
  260. High level waste‏‎ (2 revisions)
  261. Clearance‏‎ (2 revisions)
  262. Representative organism (non-human biota)‏‎ (2 revisions)
  263. ICRPædia Guide to the Basics of Ionising Radiation‏‎ (2 revisions)
  264. Dose constraint‏‎ (2 revisions)
  265. Early normal tissue responses‏‎ (2 revisions)
  266. Threshold dose for tissue reactions‏‎ (2 revisions)
  267. Magnetosphere‏‎ (2 revisions)
  268. Beta-minus decay‏‎ (2 revisions)
  269. Clearance level‏‎ (2 revisions)
  270. Radiographer‏‎ (2 revisions)
  271. Representative person‏‎ (2 revisions)
  272. Safety‏‎ (2 revisions)
  273. Dose conversion coefficient‏‎ (2 revisions)
  274. Edema‏‎ (2 revisions)
  275. Specific effective energy‏‎ (2 revisions)
  276. Limitation of dose‏‎ (2 revisions)
  277. Excess relative risk‏‎ (2 revisions)
  278. Exposure situation‏‎ (2 revisions)
  279. Transmission detection system‏‎ (2 revisions)
  280. Multistage tumorigenesis‏‎ (2 revisions)
  281. Non-sphericity parameter‏‎ (2 revisions)
  282. Growth factor‏‎ (2 revisions)
  283. Alimentary tract transfer factor‏‎ (2 revisions)
  284. Pharynx‏‎ (2 revisions)
  285. Beta-plus decay‏‎ (2 revisions)
  286. Calculating Doses from Intakes of Radionuclides‏‎ (2 revisions)
  287. Cumulative dose‏‎ (2 revisions)
  288. Reproductive integrity‏‎ (2 revisions)
  289. Safety case‏‎ (2 revisions)
  290. Slow repair‏‎ (2 revisions)
  291. Effect Dose 50‏‎ (2 revisions)
  292. Isotropic geometry‏‎ (2 revisions)
  293. Endogeneous excretion‏‎ (2 revisions)
  294. Lineal energy‏‎ (2 revisions)
  295. Thyroid blocking‏‎ (2 revisions)
  296. Exposure to Radon at Home‏‎ (2 revisions)
  297. Transparency‏‎ (2 revisions)
  298. GATA binding protein 2‏‎ (2 revisions)
  299. Waste disposal‏‎ (2 revisions)
  300. Non-targeted effects‏‎ (2 revisions)
  301. Hormones‏‎ (2 revisions)
  302. Authorization‏‎ (2 revisions)
  303. Procedural values‏‎ (2 revisions)
  304. Clonogenic cells‏‎ (2 revisions)
  305. Curie‏‎ (2 revisions)
  306. Cytokines‏‎ (2 revisions)
  307. Residual dose‏‎ (2 revisions)
  308. Safety culture‏‎ (2 revisions)
  309. Solar cosmic radiation‏‎ (2 revisions)
  310. Inhalability‏‎ (2 revisions)
  311. Spontaneous fission‏‎ (2 revisions)
  312. Itinerant (radiation) worker‏‎ (2 revisions)
  313. Linear-non-threshold model‏‎ (2 revisions)
  314. Trapped particles‏‎ (2 revisions)
  315. Acute radiation syndrome‏‎ (2 revisions)
  316. Orphan source‏‎ (2 revisions)
  317. Hounsfield unit‏‎ (2 revisions)
  318. Authorized limit‏‎ (2 revisions)
  319. Planned exposure situation‏‎ (2 revisions)
  320. Progenitor cell‏‎ (2 revisions)
  321. Cardiac arrhythmias‏‎ (2 revisions)
  322. Radiation belt‏‎ (2 revisions - redirect page)
  323. Clonogenic survival‏‎ (2 revisions)
  324. Reasonableness‏‎ (2 revisions)
  325. Respiratory protection‏‎ (2 revisions)
  326. Disposal‏‎ (2 revisions)
  327. Scintigraphy‏‎ (2 revisions)
  328. Dose criteria‏‎ (2 revisions)
  329. Solar cycle‏‎ (2 revisions)
  330. Inner bremsstrahlung‏‎ (2 revisions)
  331. Environmental exposure‏‎ (2 revisions)
  332. Systemic model‏‎ (2 revisions)
  333. Linear-quadratic dose response model‏‎ (2 revisions)
  334. Exempt waste‏‎ (2 revisions)
  335. Time factor‏‎ (2 revisions)
  336. Myocardial perfusion‏‎ (2 revisions)
  337. Adaptive response‏‎ (2 revisions)
  338. What is Radon?‏‎ (2 revisions)
  339. Alveolar-interstitial region‏‎ (2 revisions)
  340. Autoimmune disease‏‎ (2 revisions)
  341. Platelet-derived growth factor‏‎ (2 revisions)
  342. ICRP Publication 118‏‎ (2 revisions)
  343. Cardiac valve diseases‏‎ (2 revisions)
  344. Radiation modifier‏‎ (2 revisions)
  345. Radiological protection principles‏‎ (2 revisions)
  346. DRL process‏‎ (2 revisions)
  347. Retrievability‏‎ (2 revisions)
  348. Immune system‏‎ (2 revisions)
  349. Institutional control‏‎ (2 revisions)
  350. Stakeholder‏‎ (2 revisions)
  351. Environmental radiation protection‏‎ (2 revisions)
  352. Tachycardia‏‎ (2 revisions)
  353. Exemption level‏‎ (2 revisions)
  354. Tissue equivalent material‏‎ (2 revisions)
  355. Myocardial stress test‏‎ (2 revisions)
  356. Oversight‏‎ (2 revisions)
  357. Projected dose‏‎ (2 revisions)
  358. Co-expertise‏‎ (2 revisions)
  359. Radionuclides of natural origin‏‎ (2 revisions)
  360. Connective tissue‏‎ (2 revisions)
  361. Recovery (cellular or tissue)‏‎ (2 revisions)
  362. Reversibility‏‎ (2 revisions)
  363. In vivo radiobioassay‏‎ (2 revisions)
  364. Solar particle event‏‎ (2 revisions)
  365. Effective dose equivalent‏‎ (2 revisions)
  366. Existing exposure situation‏‎ (2 revisions)
  367. Gastroschisis‏‎ (2 revisions)
  368. Worker‏‎ (2 revisions)
  369. Nuclear track detectors‏‎ (2 revisions)
  370. Angiogenesis‏‎ (2 revisions)
  371. Hyperbaric oxygen‏‎ (2 revisions)
  372. Bioturbation‏‎ (2 revisions)
  373. Cardioverter-defibrillator‏‎ (2 revisions)
  374. Radiation safety officer‏‎ (2 revisions)
  375. Radioresponsiveness‏‎ (2 revisions)
  376. Consequential late effects‏‎ (2 revisions)
  377. Recovery responder‏‎ (2 revisions)
  378. DRL value‏‎ (2 revisions)
  379. Rehabilitation of living conditions‏‎ (2 revisions)
  380. Right to know‏‎ (2 revisions)
  381. Incidence‏‎ (2 revisions)
  382. Solar wind‏‎ (2 revisions)
  383. Epithelium‏‎ (2 revisions)
  384. Target tissue‏‎ (2 revisions)
  385. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  386. Acceptance test‏‎ (2 revisions)
  387. Gastrulation‏‎ (2 revisions)
  388. Working level‏‎ (2 revisions)
  389. OLINDA/EXM‏‎ (2 revisions)
  390. Habitual mouth breather‏‎ (2 revisions)
  391. Annihilation photons‏‎ (2 revisions)
  392. Particle radiance‏‎ (2 revisions)
  393. Hyperfractionation‏‎ (2 revisions)
  394. Bone marrow‏‎ (2 revisions)
  395. Protection strategy‏‎ (2 revisions)
  396. Radiation source‏‎ (2 revisions)
  397. Cohort study‏‎ (2 revisions)
  398. Radiosensitiser‏‎ (2 revisions)
  399. ICRP Publication 25‏‎ (1 revision)
  400. Relative biological effectiveness‏‎ (1 revision)
  401. ICRP Publication 31‏‎ (1 revision)
  402. Deterministic effect‏‎ (1 revision)
  403. ICRP Publication 98‏‎ (1 revision)
  404. ICRP Publication 46‏‎ (1 revision)
  405. ICRP Publication 60‏‎ (1 revision)
  406. Dose modifying factor‏‎ (1 revision)
  407. Somatic effect‏‎ (1 revision)
  408. ICRP Publication 75‏‎ (1 revision)
  409. ICRP Publication 9‏‎ (1 revision)
  410. Targeted effects‏‎ (1 revision)
  411. 1934 Recommendations‏‎ (1 revision)
  412. Access control‏‎ (1 revision)
  413. Typical value‏‎ (1 revision)
  414. General Information: Radon‏‎ (1 revision - redirect page)
  415. Particle transport‏‎ (1 revision)
  416. ICRP Publication 108‏‎ (1 revision)
  417. Brachytherapy‏‎ (1 revision)
  418. ICRP Publication 121‏‎ (1 revision)
  419. Case–control study‏‎ (1 revision)
  420. ICRP Publication 136‏‎ (1 revision)
  421. Collective dose‏‎ (1 revision)
  422. ICRP Publication 150‏‎ (1 revision)
  423. Reference Person‏‎ (1 revision)
  424. ICRP Publication 26‏‎ (1 revision)
  425. DS86‏‎ (1 revision)
  426. Relative life lost‏‎ (1 revision)
  427. ICRP Publication 32‏‎ (1 revision)
  428. ICRP Publication 99‏‎ (1 revision)
  429. ICRP Publication 47‏‎ (1 revision)
  430. Security screening‏‎ (1 revision)
  431. ICRP Publication 61‏‎ (1 revision)
  432. ICRP Publication 76‏‎ (1 revision)
  433. Stochastic effect‏‎ (1 revision)
  434. Equilibrium equivalent concentration‏‎ (1 revision)
  435. Expanded radiation field‏‎ (1 revision)
  436. 1937 Recommendations‏‎ (1 revision)
  437. Tolerance dose‏‎ (1 revision)
  438. Adventitious source‏‎ (1 revision)
  439. Occupancy factor‏‎ (1 revision)
  440. Annual intake‏‎ (1 revision)
  441. ICRP Publication 109‏‎ (1 revision)
  442. ICRP Publication 122‏‎ (1 revision)
  443. ICRP Publication 137‏‎ (1 revision)
  444. Radon-prone area‏‎ (1 revision)
  445. ICRP Publication 151‏‎ (1 revision)
  446. ICRP Publication 27‏‎ (1 revision)
  447. Relative risk‏‎ (1 revision)
  448. ICRP Publication 33‏‎ (1 revision)
  449. Detriment-adjusted risk‏‎ (1 revision)
  450. Ring chromosome‏‎ (1 revision)
  451. ICRP Supporting Guidance 2‏‎ (1 revision)
  452. ICRP Publication 48‏‎ (1 revision)
  453. Dose-response function‏‎ (1 revision)
  454. ICRP Publication 62‏‎ (1 revision)
  455. International Commission on Radiological Protection‏‎ (1 revision)
  456. ICRP Publication 77‏‎ (1 revision)
  457. Lag‏‎ (1 revision)
  458. Equilibrium factor‏‎ (1 revision)
  459. Teratocarcinoma‏‎ (1 revision)
  460. Low dose‏‎ (1 revision)
  461. 1950 Recommendations‏‎ (1 revision)
  462. Backscatter factor‏‎ (1 revision)
  463. Potentially lethal damage repair‏‎ (1 revision)
  464. ICRP Publication 10A‏‎ (1 revision)
  465. ICRP Publication 123‏‎ (1 revision)
  466. Charged-particle equilibrium‏‎ (1 revision)
  467. ICRP Publication 138‏‎ (1 revision)
  468. Collimation‏‎ (1 revision)
  469. ICRP Publication 152‏‎ (1 revision)
  470. ICRP Publication 28‏‎ (1 revision)
  471. Relative survival‏‎ (1 revision)
  472. ICRP Publication 34‏‎ (1 revision)
  473. ICRP Publication 49‏‎ (1 revision)
  474. ICRP Publication 63‏‎ (1 revision)
  475. Source region‏‎ (1 revision)
  476. ICRP Publication 78‏‎ (1 revision)
  477. Elemental dose‏‎ (1 revision)
  478. Late normal tissue responses‏‎ (1 revision)
  479. Exposed individuals‏‎ (1 revision)
  480. 1954 Recommendations‏‎ (1 revision)
  481. Α/β value‏‎ (1 revision)
  482. Oncogene‏‎ (1 revision)
  483. Apoptosis‏‎ (1 revision)
  484. ICRP Publication 11‏‎ (1 revision)
  485. ICRP Publication 124‏‎ (1 revision)
  486. ICRP Publication 139‏‎ (1 revision)
  487. ICRP Publication 153‏‎ (1 revision)
  488. ICRP Publication 29‏‎ (1 revision)
  489. ICRP Publication 35‏‎ (1 revision)
  490. ICRP Publication 5‏‎ (1 revision)
  491. Dose-threshold hypothesis‏‎ (1 revision)
  492. Severe deterministic injury‏‎ (1 revision)
  493. ICRP Publication 64‏‎ (1 revision)
  494. Intervention‏‎ (1 revision)
  495. ICRP Publication 79‏‎ (1 revision)
  496. Sublethal damage repair‏‎ (1 revision)
  497. 1956 Recommendations‏‎ (1 revision)
  498. Transfer of risk‏‎ (1 revision)
  499. Molecular imaging‏‎ (1 revision)
  500. Activation‏‎ (1 revision)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://icrpaedia.org/Special:MostRevisions"